August 20, 2020 -- The Hennessy Group, an executive search firm specializing in life sciences, announced the recent placements of key executives at three leading biopharmaceutical companies.
Paul Korner, MD, MBA, was placed as Chief Medical Officer with Agile Therapeutics, a cutting-edge women's healthcare company. In this new position, Dr. Korner will support the commercial launch of Agile's initial product, Twirla®, broaden the Company's product development pipeline, and evaluate external growth opportunities. Dr. Korner is a board-certified OB/GYN with over 20 years of experience in the global pharmaceutical and biotech industries, where he developed over 50 clinical trials and aided in the commercial launch of 10 products, including some of the most recognizable products in the women’s reproductive health market. Previously, he served in leadership roles with Solvay Pharmaceuticals, Wyeth Research, Bayer, Ferring Pharmaceuticals, and Axovant Gene Therapies.
Alessandro Lobbia joined specialty pharma company, Pacira BioSciences, as Vice President, Regulatory CMC. With over 20 years of regulatory CMC experience in both domestic and international markets, Mr. Lobbia has directed regulatory CMC activities at Neurocrine Biosciences, Tocagen, Cadence Pharmaceuticals, Favrille, Biogen, and IDEC Pharmaceuticals. In his new role, Mr. Lobbia oversees and manages Pacira’s regulatory affairs CMC departmental activities, and implements and maintains the company’s global CMC regulatory procedures and systems.
Pol F. Boudes, MD, a renowned expert in clinical drug development for liver-related diseases, joined Galectin Therapeutics, a leader in NASH therapeutics, as Chief Medical Officer. With over 25 years in drug development, Dr. Boudes holds several records of invention, including inventing and launching programs in rare liver diseases during his time as CMO at CymaBay Therapeutics where he worked on that company’s proprietary NASH compound. Prior to CymaBay, Dr. Boudes was CMO at Amicus Therapeutics, where he focused on therapeutics for rare lysosomal storage disorders. He also worked in clinical development for Bayer, Wyeth Research, Hoffman-La Roche, and Pasteur Merieux. Dr. Boudes has contributed to the approval of multiple drugs, both in the U.S. and globally, across a variety of therapeutic indications.
"The Hennessy Group is proud to contribute to the continued success of Agile, Pacira, and Galectin by placing known experts and leaders in these important roles. Each search was conducted during a significant growth period for these three dynamic companies. I am proud of the collaboration and unity we had with each client team to deliver the top-tier talent these companies sought during such crucial and exciting times in their respective development," said Robert Hennessy, CEO of The Hennessy Group.
Known for candidate care and development, guaranty of fit, and high placement stick rate, The Hennessy Group has been placing leaders in the life sciences industry for over 20 years. Contact us at [email protected] to learn more.
